Germline mutations in mismatch repair (MMR) genes, tumours with high microsatellite instability (MSI-H) and loss of MMR protein expression are the hallmarks of HNPCC (Lynch syndrome). While somatic MLH1 promoter hypermethylation is generally accepted in the tumorigenesis of sporadic tumours, abnormal MLH1 promoter methylation in normal body cells is controversially discussed as a mechanism predisposing patients to HNPCC. In all 94 patients suspected of HNPCC-syndrome with a mean age of onset of 45.5 years, MLH1-deficiency in their tumours but no germline mutation, underwent methylation-specific PCRscreening for MLH1 promoter methylation. In peripheral blood cells of 12 patients an MLH1 promoter methylation, in seven informative cases allele-specific, was found. Normal colonic tissue, buccal mucosa, and tumour tissue available from three patients also presented abnormal methylation in the MLH1 promoter. The heredity of aberrant methylation is questionable. Pro: MLH1 promoter methylation was found in a patient and his mother giving evidence for a familial predisposition for an epimutation in MLH1. Contra: a de novo set-up of methylation in one patient, a mosaic or incomplete methylation pattern in six patients, and no evidence for inheritance of MLH1 promoter methylation in the remaining families. Our findings provide strong evidence that MLH1 promoter methylation in normal body cells mimics HNPCC and constitutes a pathogenic pre-lesion in MLH1. The identification of hypermethylation as an epigenetic defect has important implications for surveillance recommendations, as these patients should be treated like Lynch syndrome patients, whereas the heritability of methylation is still under investigation.
Introduction
The hereditary non-polyposis colorectal cancer (HNPCC) syndrome is a familial predisposition to early-onset colorectal cancer (CRC) and tumours of the endometrium, stomach, small intestine, hepatobiliary system, ureter, renal pelvis, ovary, brain and skin (MIM No 114500). 1 Germline mutations in the DNA mismatch repair (MMR) genes MLH1, MSH2, MSH6 or PMS2 are frequently found in combination with high microsatellite instability (MSI-H) and loss of MMR protein expression in tumours. Suspicion of HNPCC is raised according to the Amsterdam criteria 2, 3 or the less stringent Bethesda guidelines. 4 MMR deficiency due to loss of MLH1 in tumour tissue may be due to a germline mutation -but may also result from gene inactivation or silencing by DNA methylation or promoter mutation. Methylation of cytosines in single CpG dinucleotides located in the promoter region of the MLH1 gene can epigenetically modify gene expression. 5, 6 The MLH1 CpG islands D and B/C (Figure 1b ) are normally unmethylated 7 while biallelic hypermethylation in the tumour tissue was found to be a causative mechanism for 15% of sporadic endometrial, 8, 9 gastric 10,11 and colorectal 10,12 -14 cancers showing MSI-H and immunohistochemical (IHC) MLH1-deficiency. The transcriptional activity of the MLH1 promoter is strongly dependent on two CAAT boxes at c.1-282 and c.1-145 bp 15 and on transcriptional enhancers in a region from c.1-250 to c.1-151 bp 16 ( Figure 1a ). Another possibility for silencing would be promoter mutations, which have so far not been discovered. 16 -18 The CpG island methylator phenotype (CIMP) describes the hypermethylation of many CpG islands and the silencing of multiple genes, which is a result of the imbalance between methylation protection and de novo methylation activity. 19, 20 CIMP cancers include a majority of tumours with sporadic MMR deficiency through hypermethylation of the MLH1 promoter, but also include tumours without microsatellite instability. 21 Besides methylation of the MLH1 promoter in tumour cells, epigenetic silencing of MLH1 in normal body cells is discussed as a novel predisposition to MLH1 deficiency and CRC. Eleven cases of hemiallelic hypermethylation in the MLH1 promoter region in peripheral blood of patients with early-onset of CRC or HNPCC-associated endometrial cancer have been reported in the literature. 22 -27 We add the so far largest number of a further 12 patients to this list, which not only helps to prove that aberrant methylation in the MLH1 promoter is an alternative pathomechanism for the HNPCC phenotype but also helps to better define the specific clinical features of these cases, including heritability. Furthermore, this is the second report of a maternal transmission of an MLH1 promoter methylation, excluding a de novo methylation by chance and pointing towards a familial and heritable predisposition for an epimutation in MLH1.
Materials and methods

Patients and material
Patients were recruited in six centers of the German HNPCC consortium. All patients gave written informed consent for the study, approved by the ethics committees.
94 CRC patients (51 males, 43 females, mean age 45.5, SD 33.5 years) with IHC loss of MLH1 expression and MSI-H tumours were included in this study. Of those, 16 fulfilled the Amsterdam criteria and the others met at least one of the revised Bethesda criteria. Tumour localisation was right-sided (proximally of the splenic flexure) in 75% of the cases. The BRAF mutation p.V600E which is associated with sporadic MLH1 inactivation via methylation was excluded in the tumours of all 27 patients available. 28 DNA from peripheral blood cells was extracted using the Flexigene kit (Qiagen), DNA from buccal mucosa was extracted using the QIAamp DNA Blood Mini kit (Qiagen). DNA extraction of tumour tissue and normal tissue from paraffin-embedded material was done by microdissection. 29 Microsatellite analyses and immunohistochemical staining MSI-analysis and IHC-staining was done as described. 4, 30 Mutation and deletion screening of the MLH1 gene and promoter Mutation screening of the MLH1 gene was done by DHPLC analyses 31 or by direct sequencing. Deletion or duplication analysis of the MLH1 and MSH2 gene with an MLPA assay was published previously. 32 The MLH1 core promoter is located between c.1-300 and c.1-140 bp. 15, 16, 33 For amplification and sequencing of the region including c.1 -667 to c.1 -26 bp (Figure 1a and Supplementary Table 1 ), a standard touchdown PCR protocol 34 was performed.
Bisulphite treatment and methylation analyses Sodium bisulphite treatment was performed as published, 35 followed by methylation status-specific PCR (MSP) (Figure 1c) . 34 cDNA expression analysis Total RNA was extracted from peripheral blood by the PAX Gene Blood RNA and preparation kit (PreAnalytix), cDNA was generated with the first-strand cDNA-Synthesis kit (Amersham Biosciences). 35 Analysis of SNP rs1799977 in exon 8 was performed with cDNA primers 7/8forward and 9reverse (Supplementary Table 1 ) in a standard procedure 34 followed by sequencing.
Haplotype analyses
To determine the haplotypes 4 markers D3S1260, D3S1283, D3S3518, and D3S1611 and SNPs rs1800734, rs35032294, and rs1799977 were investigated in DNA of all family members available.
Primer sequences are available in the Supplementary Table 1 or upon request.
Results
The study cohort consisted of 94 unrelated Bethesdapositive patients with MSI-H tumours, loss of MLH1 protein expression and a negative result in mutation-and deletion-screening in MLH1. The BRAF mutation p.V600E, frequently associated with sporadic MLH1 methylation, was excluded in the tumours available from 27 patients, including patients 1, 2, 3, 4, and 12 of Table 1 .
Sequence analysis of the MLH1 promoter Potential transcription factor-binding sites are located in a region of up to c.1-900 bp according to TESS (www.cbil. upenn.edu/cgi-bin/tess/tess) ( Figure 1 ). To screen for functional mutations in the MLH1 promoter, sequence analysis of a fragment from c.1 -667 to c.1 -26 bp relative to the translation start of MLH1 was performed. The heterozygous sequence alteration rs35032294 at c.1-269C4G 18 was found in individual 6 ( Table 1) . A common SNP rs1800734 39 at c.1-93G/A relative to the translation start site of MLH1, was found to be heterozygote in 41 cases (44%), homozygote A in 11 cases (12%) and homozygote G in 41 cases (44%). 90 control individuals showed an allelic distribution for the SNP c.1-93G/A similar to that of our HNPCC cohort, 3% showed the heterozygote c.1-269C/G SNP.
CpG island prediction
Analysis of the MLH1 promoter with the prediction programs MethPrimer 40 and EMBOSS CpGplot 41 resulted in three CpG-islands depicted in grey boxes in Figure 1b . Alternatively, one large CpG island of 1128 bp was described by the UCSC Genome Browser. 42 CpG islands D and B/C, both downstream of c.1-500 bp are unmethylated in normal cells. 7, 43 Abnormal methylation of these CpG dinucleotides causes transcriptional silencing, whereas in the upstream CpG island A/B (c.1 -755 to c.1 -574 bp), methylation is not relevant for MLH1 transcription regulation. Figure 2a ) but was still heterozygous in two cases (Table 1 , patients 9 and 12, Figure 2b ). This finding denotes an allele-specific methylation, which might not be complete in all hematopoietic cells -indicating a mosaic methylation pattern in two patients. Patient 6, carrying the heterozygous sequence alteration c.1-269C4G, showed a complete and allele-specific methylation of only the variant c.1-269G allele in MSP-M1, while MSP-U1 monoallelically represented the c.1-269C allele (Table 1) .
Methylation was also found in buccal mucosa and normal colonic tissue in three methylation-positive cases analysed. Analysis of the tumour tissues of these patients also revealed methylated and unmethylated alleles. No methylation of the MLH1 promoter was found in 82 patients and 75 healthy control subjects.
The methylation-specific multiplex ligation-dependent probe amplification (MS-MLPA ME011) assay was used for quantification of aberrant methylation in single CpG-dinucleotides in the MLH1 promoter, data are displayed in detail in Supplementary Figure 2 . The average Inheritance of MLH1 methylation in one of 12 cases M Morak et al percentage of methylation was 45 -55% in the five patients (1, 5, 6, 7, and 10) with complete methylation of one allele found by allele-specific sequencing of promoter SNPs. For those three patients (8, 9 , and 12) with supposed mosaic methylation, MS-MLPA analysis revealed methylation of 19 -31% supporting our previous data. The data for four patients without SNPs revealed full methylation in patient 2 and methylation of 10 -20% in patients 3, 4, 11 and the mother of patient 4, which are therefore also assumed to be mosaic.
MLH1 cDNA expression
The allelic expression of MLH1 cDNA was analysed in two methylation-positive patients, both heterozygous for the SNP (c.655A4G; I219V; rs1799977) in MLH1 exon 8. CDNA-sequencing detected a monoallelical expression of the c.655G allele of MLH1 for patient 1 (Figure 3a) , indicating a complete transcriptional silencing of the c.655A allele, whereas patient 8 showed a signal reduction of approximately 50%, indicating an incomplete transcriptional silencing of the c.655G allele (Figure 3b ). 
Inheritance of MLH1 methylation in one of 12 cases M Morak et al
Family studies Blood samples of eight first degree relatives of five methylation carriers revealed methylation in the MLH1 promoter in one case (for details see Supplementary Figure  1 ). The mother of patient 4 showed methylation in blood cells and no external hint to be affected at age 64 but was sent to colonoscopy. For patient 3, the methylation could not be linked to one allele but his three healthy sons inherited different paternal alleles and were all methylation negative. The methylated allele of patient 9 was derived from her healthy mother who is methylation negative. The son of patient 6 showed no methylation but had inherited the allele unmethylated in his father.
The methylated allele of patient 5 was inherited from her affected mother (cervical cancer at age 33, colon cancer at age 64 without MSI and without loss of MMR protein expression in the CRC), but in the mother the allele was unmethylated. The healthy brother had an unmethylated MLH1 promoter and did not carry the allele methylated in his sister.
Clinical phenotypes of methylation-positive patients
The clinical phenotypes of the patients are summarised in Table 1 . None of the 12 methylation-positive patients fulfilled the Amsterdam criteria, but four patients had one or two family members with gastrointestinal malignancies (Table 1) . Eight CRCs were right-sided (proximal to the splenic flexure) and four left-sided primary tumours. Synor metachronous CRCs were diagnosed in 50% of the patients. The mean age at tumour diagnosis was 39±19 years SD.
Discussion
We report the so far largest cohort of unrelated HNPCCsuspected individuals with hypermethylation of the proximal promoter region of the MLH1 gene in peripheral blood cells. This doubles the number of cases reported to date. 22 -27 Seven of the 12 patients had promoter SNPs, which enabled us to prove allele-specific hemiallelic methylation in peripheral blood cells (mesodermal). For three patients endodermal tissues (colonic or buccal mucosa) were available and also methylation-positive. A pan-cellular, allele-specific hypermethylation of the MLH1 promoter in different germ cell lineages was previously described for nine patients. 22 -27 Monoallelic MLH1 expression could be shown in one of our patients, which was also found in three cases in the literature. 22, 24, 27 For the first time, we report two patients with evidence of a mosaic methylation pattern on one allele for the MLH1 promoter using a SNP at position c.1-93. This incomplete methylation might be due to a clonal expansion of methylated and unmethylated cells, or to a loss or gain of methylation as a somatic event in hematopoietic cells. One further patient revealed an incomplete silencing of a coding SNP in cDNA exon 8, again indicating an inconsistent methylation pattern. The results of methylation extent gained by methylation-specific multiplex ligation-dependent probe amplification (MS-MLPA) supported our previous findings by MSP-sequencing. Further three patients without SNPs analysed by MS-MLPA revealed a mosaic methylation pattern. A possible explanation might be a de novo methylation event after fertilisation, which leads to a clonal or mosaic methylation.
Furthermore, we could show in three patients that inactivation of the second allele in the tumour tissue is due to a mechanism independent of methylation, as no methylation for the second allele was detectable in the three tumour tissues analysed.
Methylation is an epigenetic modification of the DNA which is passed on in somatic mitosis, but it is reversible, considering the comprehensive remodification processes of genomic methylation that occur between primordial germ cell formation and the preimplantation embryo. 44 -46 The family history of methylation carriers was negative in eight of our cases as well as in nine of 11 cases reported in the literature. 22, 24, 25 Inheritance was analysed in literature in 11 families, but so far only in one family a maternal transmission of the methylation in the MLH1 promoter could be proven. 22, 24, 27 For the patients studied here, we were able to analyse inheritance in eight family members. The finding of MLH1 promoter methylation in a mother and her son implicates a maternal transmission of methylation, while methylation erasure was found in the three methylation negative sons with different paternal alleles of a methylation-positive father. In two families a de novo set up of methylation in maternal alleles was found. One daughter had a mosaic or incomplete methylation, while the daughter of the other family showed a complete methylation of the de novo methylated allele. We suspect a methylation event by chance without familial segregation and a low risk of transmission as four allele-sharing siblings published previously and six family members described here, were discordant in respect to MLH1 promoter methylation. 22, 27 Strikingly, we found incomplete methylation (8%) in the 64-year-old mother of patient 4 (10% methylation) hinting towards a heritable predisposition to an epimutation in MLH1 eventually due to (1) a maternally transmitted germline methylation or (2) a methylation-inducing mechanism in cis caused by the genetic environment.
A striking transmission of mosaic methylation in the promoter of MSH2 has been reported in one family over three generations and further investigations are necessary to clarify the cause of inheritance of only mosaic and low-level methylation in blood. 47 Here, one could argue for a possible partial erasure of methylation in highly proliferative cells, accompanied by a consistent methylation in germ cells. We could not find mosaic and lowlevel methylation in blood of siblings. Nevertheless, the negative or weak family history in the majority of our cases, the consideration that six patients display a mosaic methylation in hematopoietic cells and the fact that de novo methylation was shown in two cases, underlines that inheritance of a predisposition to an epimutation for MLH1 promoter hypermethylation is a rare event. The erasure of methylation in gametogenesis found in the sons of methylation-carrier 3 is supported by methylation patterns of either 0 or 1% in the spermatozoa of two methylation carriers. 22 The incomplete erasure of methylation (1%) might be an artefact as well. 48 CpG islands of some genes, among them MLH1, are more prone to methylation in several types of cancers. 7, 9, 11, 49 In this respect it is noteworthy that the methylated alleles traced back were of maternal origin in three cases in the literature 24, 27 and in one case published here. An increased maternal age at pregnancy can be excluded, as all pregnancies came prior to a maternal age of 34 years, as well as methylation errors due to assisted reproductive techniques.
The clinical phenotypes of 12 MLH1 methylationpositive cases described here are similar to patients with pathogenic MLH1 germline mutations. 50, 51 The mean age of tumour onset was 39 years (range 30 -58 years), however, we found a high incidence of syn-/metachronous tumours in 50%. In the current literature of MLH1 promoter methylation cases 22 -27 clinical features of 11 patients revealed a mean age of onset of 32 years (range 17 -46 years) and syn-/metachronous disease in 50%. The clinical features of the six patients with a mosaic methylation pattern did not differ and were not in any sense milder; one showed the Muir-Torre phenotype and was 35 years old at tumour manifestation, the others were 35, 37, 39, 41 and 46 years old at tumour manifestation. There is increasing evidence that aberrant methylation in the promoter region of one MLH1 allele is functionally equivalent to a pathogenic MLH1 germline mutation and mimics the clinical phenotype of Lynch syndrome. To which extent the tumour risk is influenced by the mosaic methylation has to be determined. With the few data we have generated here, there is no difference in age of onset in correlation to the methylation status, mosaic or not mosaic, in blood cells. Nevertheless, there is increasing evidence that these seemingly 'sporadic' HNPCC-patients need to be treated the same way as Lynch syndrome patients in regard to clinical aspects.
Of all patients with specified pre-lesion in the MLH1 gene 2% have an aberrant MLH1 promoter methylation in their normal cells, the others are carriers of pathogenic germline point mutations or deletions in MLH1. Aberrant methylation of promoters has hitherto been rarely found and investigated, but in the thus far largest cohort analysed constitutes 13% of patients with suspected HNPCC-syndrome without MLH1 germline mutation but with MLH1-deficient and MSI-H tumours. Therefore, methylation analysis of the MLH1 promoter should be performed for all early-onset or multiple colorectal cancer patients with MSI-H tumours, and loss of IHC MLH1 protein expression of unknown cause. At least first degree relatives of methylation-positive should be offered the MLH1 promoter methylation analysis to exclude the rare event of inheritance of a familial epimutation, as found in one of our cases.
